Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on February 13, 2018. The filing reports the entry into a material definitive agreement regarding a public offering of securities.
Key Financial Metrics and Transaction Details
The filing details a firm commitment underwritten public offering with the following terms:
- Securities Issued: 5,000,000 shares of common stock and warrants to purchase up to 3,500,000 shares of common stock.
- Warrant Terms: Exercise price of $3.00 per share; exercisable immediately for a period of five years.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 750,000 shares of common stock and warrants to purchase up to 525,000 shares.
- Net Proceeds: Expected to be approximately $9.4 million before the exercise of the over-allotment option, after deducting underwriting discounts, commissions, and estimated expenses.
- Closing Date: Expected on February 15, 2018.
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the execution of the Underwriting Agreement with Roth Capital Partners, LLC, which will result in the issuance of new equity and warrants, increasing the company's capital base upon closing.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the expected net proceeds from the offering. Management notes that these statements involve risks and uncertainties, including various risks detailed in the Company's other SEC filings. The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received, as the $9.4 million figure is an estimate prior to the over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) and Warrant form (Exhibit 4.1) for specific covenants and conditions.
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Check subsequent filings to determine if the over-allotment option was exercised.